Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

A Multi-Center Study to Evaluate the Safety and Efficacy of a Urine DEK ELISA in Diagnosis of Subjects With Bladder Cancer

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01563796

Enrollment

1115

Registered

2012-03-27

Start date

2012-03-31

Completion date

2016-10-15

Last updated

2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer, Dysuria, Hematuria

Keywords

bladder cancer, TCC, urine, protein ELISA

Brief summary

The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in the urine of patients suspected of having bladder cancer. The measurement of urine DEK protein, relative to an established cut-off, is correlated with the presence or absence of bladder cancer.

Detailed description

Sample Collection: Urine samples used in the study will be collected immediately prior to the urological evaluation procedure and stored at -80 oC. Urine samples will be sent to sponsor and remain at -80o C until analysis. Clinical Data Collection: All subject and clinical information will be recorded on the form in section 9.3. Enrollment Checklist and Case Report Form (CRF). Information regarding the history of hematuria and urine cytology will be recorded. In addition, non-identifying information including age, sex, race, smoking history, alcohol consumption, occupational exposure to chemicals or dyes, history of urologic disorder or disease, history of irritative voiding symptoms, history of urinary tract infection, history of pelvic irradiation, and analgesic abuse will be recorded. The Investigators will also be asked to provide information from the subjects' medical records for up to one (1) year after their enrollment and sample collection. In particular, diagnosis of TCC, other malignant diseases, or non-malignant urogenital conditions will be provided.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are at least twenty-five (25) years of age with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones.

Exclusion criteria

* Females who are pregnant (ascertained by history) * Females who are menstruating or within three (3) days of their last menstruation * Patients who have undergone invasive procedures of the urogenital tract in the past two (2) months * Patients with a history of transitional cell carcinoma (TCC) of the urinary tract

Design outcomes

Primary

Measure	Time frame
Histology	Up to 1 year after cystoscopy/biopsy

Secondary

Measure	Time frame
Cystoscopy	up to 3 months after collection
Cytology	up to 3 months after collection

Countries

United States

Outcome results